Crestline Management LP purchased a new stake in Radius Health Inc (NASDAQ:RDUS) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 68,647 shares of the biopharmaceutical company’s stock, valued at approximately $2,181,000. Crestline Management LP owned 0.15% of Radius Health at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also bought and sold shares of RDUS. Consonance Capital Management LP acquired a new position in Radius Health during the fourth quarter worth $84,168,000. TimesSquare Capital Management LLC raised its holdings in Radius Health by 184.6% during the third quarter. TimesSquare Capital Management LLC now owns 1,610,365 shares of the biopharmaceutical company’s stock worth $62,080,000 after purchasing an additional 1,044,615 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in Radius Health during the third quarter worth $17,236,000. Orbimed Advisors LLC raised its holdings in Radius Health by 59.5% during the third quarter. Orbimed Advisors LLC now owns 1,122,800 shares of the biopharmaceutical company’s stock worth $43,284,000 after purchasing an additional 418,700 shares during the last quarter. Finally, Eversept Partners LLC acquired a new position in Radius Health during the fourth quarter worth $6,179,000.
Radius Health Inc (NASDAQ RDUS) traded down $0.12 during trading on Wednesday, reaching $35.18. The company’s stock had a trading volume of 25,081 shares, compared to its average volume of 943,132. The company has a quick ratio of 4.96, a current ratio of 5.04 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $1,579.93, a P/E ratio of -6.09 and a beta of 1.19. Radius Health Inc has a one year low of $24.66 and a one year high of $49.16.
Several equities analysts recently issued reports on the company. BidaskClub raised Radius Health from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th. Morgan Stanley lifted their price objective on Radius Health from $57.00 to $61.00 and gave the stock an “overweight” rating in a report on Friday, March 2nd. ValuEngine raised Radius Health from a “strong sell” rating to a “sell” rating in a report on Friday, December 1st. Zacks Investment Research cut Radius Health from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. Finally, Citigroup assumed coverage on Radius Health in a report on Wednesday, December 6th. They set a “neutral” rating and a $30.00 price objective for the company. One analyst has rated the stock with a sell rating, six have issued a hold rating and six have given a buy rating to the stock. Radius Health has an average rating of “Hold” and an average target price of $52.22.
In related news, major shareholder Growth N. V. Biotech purchased 75,000 shares of the company’s stock in a transaction on Friday, February 9th. The stock was bought at an average price of $34.38 per share, with a total value of $2,578,500.00. Following the completion of the transaction, the insider now owns 5,773,799 shares of the company’s stock, valued at approximately $198,503,209.62. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Growth N. V. Biotech purchased 80,000 shares of the company’s stock in a transaction on Friday, March 2nd. The shares were bought at an average cost of $32.52 per share, with a total value of $2,601,600.00. Following the transaction, the insider now directly owns 5,853,799 shares of the company’s stock, valued at approximately $190,365,543.48. The disclosure for this purchase can be found here. Company insiders own 15.00% of the company’s stock.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.